<DOC>
	<DOCNO>NCT02424734</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability ceftaroline treatment Late Onset Sepsis neonates young infant age 7 &lt; 60 day</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Ceftaroline Paediatrics With Late-Onset Sepsis</brief_title>
	<detailed_description>This multicentre , multinational , open-label , single treatment arm study intravenous ( IV ) ceftaroline fosamil ampicillin , plus optional aminoglycoside choice , hospitalize neonate young infant age 7 &lt; 60 day late-onset sepsis ( LOS ) . Baseline assessment study eligibility occur within 36 hour administration first dose study therapy . Study Day 1 define 24-hour period start onset first administration study therapy . Thereafter , subsequent Study Days follow pattern . Safety assessment occur throughout study . Clinical outcome evaluation occur End-of-Therapy ( EOT ; within 24 hour completion last infusion ) Test-of-Cure ( TOC ; 8 15 day last dose study therapy ) .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Informed consent write parent ( ) legallyacceptable representative ( ) ; Male female , gestational age ≥34 week , chronological age 7 &lt; 60 day time screening ; Diagnosis sepsis within 36 hour enrolment , defined presence least 2 clinical criterion least 1 laboratory criterion presence result suspect proven bacterial infection require IV antibiotic therapy ; Patients must meet least 2 follow clinical criterion : Hypothermia ( &lt; 36°C ) OR fever ( &gt; 38.5°C ) ; Bradycardia OR tachycardia OR rhythm instability ; Urine output 0.5 1 mL/kg/h OR hypotension OR mottle skin OR impair peripheral perfusion ; Petechial rash OR sclerema neonatorum ; New onset worsen apnoea episode OR tachypnoea episode OR increase oxygen requirement OR requirement ventilation support ; Feeding intolerance OR poor sucking OR abdominal distension ; Irritability ; Lethargy ; Hypotonia : Patients must meet least 1 follow laboratory criterion : White blood cell count ≤4,000 × 109/L OR ≥20,000 × 109/L ; Immature total neutrophil ratio &gt; 0.2 ; Platelet count ≤100,000 × 109/L ; Creactive protein ( CRP ) &gt; 15 mg/L OR procalcitonin ≥2 ng/mL ; Hyperglycaemia OR Hypoglycaemia ; Metabolic acidosis . Documented history hypersensitivity allergic reaction βlactam antibiotic aminoglycoside ; At study entry , confirm infection pathogen know resistant combination ceftaroline fosamil , ampicillin , optional aminoglycoside choice OR confirm viral , fungal , parasitic pathogen sole cause infection ; Refractory septic shock within 24 hour enrolment resolve 60 minute vasopressor therapy ; Moderate severe renal impairment define serum creatinine ≥2 time upper limit normal ( × ULN ) age OR urine output &lt; 0.5 mL/kg/h ( measure least 8 hour ) OR requirement dialysis ; Evidence progressively fatal underlying disease , life expectancy ≤60 day ; Documented history seizure ; Requiring currently take antiretroviral therapy human immunodeficiency virus ( HIV ) child HIV positive mother ; Proven suspect central nervous system ( CNS ) infection ( eg , meningitis , brain abscess , subdural abscess ) , osteomyelitis , endocarditis , necrotizing enterocolitis ( NEC ) ; Any condition ( eg , cystic fibrosis , urea cycle disorder ) , antepartum/peripartum factor , procedure would , opinion investigator , make patient unsuitable study , place patient risk , compromise quality data ; Patient 's parent ( ) legallyacceptable representative ( ) involvement plan and/or conduct study ( applies AstraZeneca staff and/or staff study site ) . Concurrent participation another clinical study investigational product ( IP ) , previous enrolment/participation study , participation another study ceftaroline fosamil within 14 day intend start first dose study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>59 Days</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Late-onset Sepsis</keyword>
</DOC>